https://www.forbes.com/sites/simonogus/2019/07/03/sports-data-startup-orreco-signs-multi-year-partnership-with-the-atlanta-hawks/
In the technological race to develop whatever edge is necessary for that “extra 1%”, professional sports teams have looked far and wide to uncover any methods will give their players an advantage on the court or on the field. This includes the collection and analysis of large amounts of data and making game decisions based on those analytics, instead just on instinct. Increasingly it is encompassing bio-analytical evaluations of players to make sure they are in peak physical condition for a match or game.
Irish-based sports technology company Orreco is one of the leaders in the bio-analytical space. It was announced earlier this week that the company has signed a “significant” multi-year partnership with the NBA’s Atlanta Hawks. The partnership will include Orreco providing the Hawks with bio-analytical services to analyze the health of their players and to eventually use the data to provide actionable solutions to accelerate player recovery. In addition, Hawks’ athletes will be monitored with the objective of prolonging their NBA careers by maintaining their bodies more effectively.
Under the terms of the deal, Orreco will use their products, called Zone and TrackOr, to support the Hawks’ training efforts. They will also provide data insights for optimizing performance and reducing the number of training sessions needed for a player or games lost due to injury during the 82-game NBA season. The way Orreco’s products work is the company profiles an athlete’s bio-markers in their blood and then feeds the information into its machine learning software. This will provide insights into optimal training conditions as well as even fine tuning sleep patterns and diet, as well as training programs that can be customized for each player as the system gathers more repetitions through data.
Orreco continues to build out its client list and has worked for several years in the NBA, such as the NBA’s Dallas Mavericks, and other sports teams including the Newcastle United of the English Premier League, USA Swimming and the New Zealand senior women’s rugby team. The Atlanta Hawks, which recently selected DeAndre Hunter as the fourth overall pick in the NBA Draft, will use the Orreco technology to evaluate their young team with an eye towards being a contender for a playoff spot in the NBA’s Eastern Conference next season.
I am delighted that the Atlanta Hawks are partnering with Orreco for our bio-analytics," said Chelsea Lane, Atlanta Hawks Executive Director of Athletic Performance and Sports Medicine. "I selected Orreco as they are world leaders in bio-analytics. They possess unrivaled expertise interpreting bio-marker data and have critically peer-reviewed published science highlighting their work with elite athletes. Our goal is to help our players understand how their recovery status impacts their performance and using this data to truly individualize their training. We are very excited that Orreco has come on board as we at the Hawks enter a new chapter in our history.”
Orreco was founded back in 2009 by sports scientist Brian Moore and consultant hematologist Andy Hodgson. The company currently has operations in Galway, Ireland, London, and a United State headquarters in Los Angeles. Orreco has raised over $4.5 million to date, including a recent $2 million funding round led by venture capital firm True Ventures. It is also backed by golfer Graeme McDowell.
“Our new partnership with the Atlanta Hawks is an exciting development for team Orreco”, said Orreco CEO Dr. Brian Moore. “We look forward to working with Chelsea and her team supporting the Atlanta Hawks to make real-time data-driven decisions leveraging bio markers and artificial intelligence.”
The practice of utilizing athlete’s blood samples as an evaluation tool is relatively new, but one with both considerable upside and drawbacks. The benefits are fairly obvious. Teams will be able to collect immense amounts of information about their players and detect potential injury factors in an analytical fashion, without bias, in the sense that players often try to play through an injury.
The downside, though, is what is done with the data after it is recorded and stored. Players don’t play for teams forever and with free agency and the competitive landscape of the NBA, a team player can quickly become an opponent. These concerns don’t even address teams potentially using this data in contract negotiations or contract issues. These methods seem to be here to stay, however, and it will be up to the teams and leagues to create governing rules for the utilization and storage of all this new data.
https://www.forbes.com/sites/simonogus/2019/07/03/sports-data-startup-orreco-signs-multi-year-partnership-with-the-atlanta-hawks/ In the technological race to develop whatever edge is necessary for that “extra 1%”, professional sports teams have looked far and wide to uncover any methods will give their players an advantage on the court or on the field. This includes the collection and analysis of large amounts of data and making game decisions based on those analytics, instead just on instinct. Increasingly it is encompassing bio-analytical evaluations of players to make sure they are in peak physical condition for a match or game. Irish-based sports technology company Orreco is one of the leaders in the bio-analytical space. It was announced earlier this week that the company has signed a “significant” multi-year partnership with the NBA’s Atlanta Hawks. The partnership will include Orreco providing the Hawks with bio-analytical services to analyze the health of their players and to eventually use the data to provide actionable solutions to accelerate player recovery. In addition, Hawks’ athletes will be monitored with the objective of prolonging their NBA careers by maintaining their bodies more effectively. Under the terms of the deal, Orreco will use their products, called Zone and TrackOr, to support the Hawks’ training efforts. They will also provide data insights for optimizing performance and reducing the number of training sessions needed for a player or games lost due to injury during the 82-game NBA season. The way Orreco’s products work is the company profiles an athlete’s bio-markers in their blood and then feeds the information into its machine learning software. This will provide insights into optimal training conditions as well as even fine tuning sleep patterns and diet, as well as training programs that can be customized for each player as the system gathers more repetitions through data. Orreco continues to build out its client list and has worked for several years in the NBA, such as the NBA’s Dallas Mavericks, and other sports teams including the Newcastle United of the English Premier League, USA Swimming and the New Zealand senior women’s rugby team. The Atlanta Hawks, which recently selected DeAndre Hunter as the fourth overall pick in the NBA Draft, will use the Orreco technology to evaluate their young team with an eye towards being a contender for a playoff spot in the NBA’s Eastern Conference next season. I am delighted that the Atlanta Hawks are partnering with Orreco for our bio-analytics," said Chelsea Lane, Atlanta Hawks Executive Director of Athletic Performance and Sports Medicine. "I selected Orreco as they are world leaders in bio-analytics. They possess unrivaled expertise interpreting bio-marker data and have critically peer-reviewed published science highlighting their work with elite athletes. Our goal is to help our players understand how their recovery status impacts their performance and using this data to truly individualize their training. We are very excited that Orreco has come on board as we at the Hawks enter a new chapter in our history.” Orreco was founded back in 2009 by sports scientist Brian Moore and consultant hematologist Andy Hodgson. The company currently has operations in Galway, Ireland, London, and a United State headquarters in Los Angeles. Orreco has raised over $4.5 million to date, including a recent $2 million funding round led by venture capital firm True Ventures. It is also backed by golfer Graeme McDowell. “Our new partnership with the Atlanta Hawks is an exciting development for team Orreco”, said Orreco CEO Dr. Brian Moore. “We look forward to working with Chelsea and her team supporting the Atlanta Hawks to make real-time data-driven decisions leveraging bio markers and artificial intelligence.” The practice of utilizing athlete’s blood samples as an evaluation tool is relatively new, but one with both considerable upside and drawbacks. The benefits are fairly obvious. Teams will be able to collect immense amounts of information about their players and detect potential injury factors in an analytical fashion, without bias, in the sense that players often try to play through an injury. The downside, though, is what is done with the data after it is recorded and stored. Players don’t play for teams forever and with free agency and the competitive landscape of the NBA, a team player can quickly become an opponent. These concerns don’t even address teams potentially using this data in contract negotiations or contract issues. These methods seem to be here to stay, however, and it will be up to the teams and leagues to create governing rules for the utilization and storage of all this new data.
